EP1140946A2 - Composes - Google Patents

Composes

Info

Publication number
EP1140946A2
EP1140946A2 EP99964526A EP99964526A EP1140946A2 EP 1140946 A2 EP1140946 A2 EP 1140946A2 EP 99964526 A EP99964526 A EP 99964526A EP 99964526 A EP99964526 A EP 99964526A EP 1140946 A2 EP1140946 A2 EP 1140946A2
Authority
EP
European Patent Office
Prior art keywords
pyrazin
formula
quinoline
octahydropyrrolo
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99964526A
Other languages
German (de)
English (en)
Inventor
Laramie Mary Gaster
Tom Daniel Heightman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1140946A2 publication Critical patent/EP1140946A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Definitions

  • the present invention relates to novel quinoline derivatives, processes for their preparation, and pharmaceutical compositions containing them.
  • US patent 5,703,072 discloses bicyclic nonane and decane compounds having dopamine receptor affinity which are claimed to be of use in the treatment of schizophrenia.
  • WO 98/50358, WO 98/50346, WO 98/47868, WO 98/47885 and WO 98/50343 all disclose a series of novel compounds which are claimed to possess combined 5-HTi A, 5-HTi ⁇ and 5- HTi jj receptor antagonist activity and are useful in the treatment of various CNS disorders.
  • WO 97/36867 and WO 98/14433 both disclose a series of lactam derivatives that are claimed to be selective agonist or antagonists of one or both of 5-HTi A and 5-HTI D receptors.
  • the present invention therefore provides a compound of formula (I) or a salt thereof:
  • P* is phenyl, bicyclic aryl, C ⁇ .gcycloalkyl, a 5 to 7 membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a bicyclic heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur;
  • Ci.galkyl is halogen, Ci.galkyl, C3_6cycloalkyl, C galkoxy, hydroxy, hydroxyCi.galkyl, hydroxyC ⁇ _6alkoxy, C ⁇ galkoxyCi - alkoxy, Ci.galkanoyl, NO , CF3, CN, SR 9 , SOR 9 , SO 2 R 9 , SO NR 10 R 1 1, CO 2 R 10 , CONRIORH , CONRlO(CH 2 ) c CO2R n , (CH 2 ) C NR 10 R 1 1 , (CH 2 ) c CONR 10 Rl l, (CH ⁇ C N ⁇ COR 1 1 , (CH 2 ) c CO 2 C ⁇ .
  • P ⁇ and P ⁇ are independently phenyl, bicyclic aryl, a 5 to 7 membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a bicyclic heterocyclic group containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur;
  • A is a bond, O, S(O) n where n is 0 to 2, carbonyl, CH 2 or NR 4 where R 4 is hydrogen or C ⁇ . galkyl;
  • R! and R2 are independently as defined above for R in formula (i); and a and b are independently 0, 1, 2 or 3;
  • L is a group of formula
  • C ⁇ _6alkyl groups whether alone or as part of another group may be straight chain or branched.
  • the term 'halogen' is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine or iodine.
  • the bicyclic aryl group represented by pl, P ⁇ or P ⁇ , which may be partially saturated, is preferably naphthyl. Where used herein the term naphthyl is intended, unless otherwise stated, to denote both naphth-1-yl and naphth-2-yl groups.
  • pl When pl is C3_6cycloalkyl preferred examples are cyclopentyl and cyclohexyl.
  • pl When pl is a 5 to 7 membered heterocyclic ring suitable examples include 5 or 6 membered heteroaryl rings such as thienyl, furyl, pyrrolyl, pyrazolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrimidyl, pyrazinyl and pyridyl.
  • Non aromatic 5 to 7 membered heterocyclic rings include pyrrolidinyl, piperidinyl or piperazinyl.
  • P s a bicyclic heterocyclic ring suitable examples include benzofused rings such as quinolinyl, isoquinolinyl, indolyl, benzofuryl, benzothienyl and benzo[l,3]dioxolyl.
  • the heterocyclic and bicyclic heterocyclic groups listed above can be linked to the remainder of the molecule via a carbon atom or, when present, a suitable nitrogen atom.
  • pl is phenyl, naphthyl, quinolyl, pyridyl or thienyl.
  • R* When a is greater than 1 the groups R* can be the same or different. Preferably a is 0, 1 or 2.
  • Preferred R! groups include halogen (particularly chlorine), a C j .galkyl group (particularly methyl), CN, CF3 or a Cj.galkoxy group (particularly methoxy or ethoxy).
  • P ⁇ and/or P ⁇ is a 5 to 7 membered heterocyclic ring or a bicyclic heterocyclic group
  • suitable examples include those listed for P above.
  • P ⁇ is phenyl, naphthyl, pyridyl, thienyl or furyl.
  • a preferred substitution arrangement for naphthyl groups is 1,4 or more preferably 1,5, that is to say, a naphth-1-yl group in which the group A is attached at the 4 or 5 position respectively.
  • P ⁇ is phenyl, pyridyl, thienyl, pyrazolyl or oxazolyl.
  • groups R! and/or R ⁇ respectively can be the same or different.
  • Preferred R! and/or R ⁇ groups include halogen (particularly chlorine), a Cj.galkyl group (particularly methyl), CN, CF3 or a Cj.galkoxy group (particularly methoxy or ethoxy).
  • A is preferably a bond or oxygen, most preferably a bond.
  • L is a group of formula:-
  • Y is preferably NH or CH 2
  • D is preferably nitrogen
  • Rbl is preferably hydrogen or together with G forms a group W referred to above.
  • X is preferably a nitrogen atom, and m is preferably 1 or 2, most preferably 1.
  • Particularly preferred compounds according to this invention are:- (S)-(-)-N-[4-(Octahydropyrrolo[l,2-a]pyrazin-2-yl)quinolin-6-yl]-3,4-dichlorobenzamide, (S)-(-)-N-[4-(Octahydropyrrolo[l,2- ⁇ ]pyrazin-2-yl)quinolin-6-yl]-3,4-dichlorobenzamide, (S)-(-)-2,3-Dihydro- 1 -[5-(2,6-dimethylpyridin-4-yl)naphth- 1 -ylcarbonyl]-8- (octahydropyrrolo[l,2- ⁇ ]pyrazin-2-yl)pyrrolo[2,3-g-]quinoline,
  • Preferred salts of the compounds of formula (I) are pharmaceutically acceptable salts. These include acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates, tartrates, citrates, oxalates, methanesulphonates and p- toluenesulphonates.
  • acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates, tartrates, citrates, oxalates, methanesulphonates and p- toluenesulphonates.
  • R a -NC( O) (IV) in which R a is as defined in formula (I) or a protected derivative thereof, with a compound of formula (V):
  • L 1 is COL a and L 2 is NH 2
  • L 1 is NH 2
  • L 2 is COL a in which L a is an appropriate leaving group.
  • one of L and L 2 is an activated carboxylic acid derivative such as an acyl chloride or acid anhydride, and the other is an amine group.
  • Activated compounds of formulae (II) and (III) can also be prepared by reaction of the corresponding carboxylic acid with a coupling agent such as dicyclohexylcarbodiimide, carbonyldiimidazole or diphenylphosphorylazide.
  • a coupling agent such as dicyclohexylcarbodiimide, carbonyldiimidazole or diphenylphosphorylazide.
  • L or O- is a group COL a where L a is halo particularly chloro.
  • reaction is conveniently effected in an organic solvent such as dichloromethane .
  • the urea forming agent can be carbonyl diimidazole, triphosgene or phosgene, and carried out in an inert organic solvent such as dimethylformamide, tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.
  • the leaving group L ⁇ is halogen e.g. chloro group and the reaction may be carried out in an inert organic solvent such as tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.
  • an inert organic solvent such as tetrahydrofuran or dichloromethane
  • a base such as triethylamine or pyridine.
  • the leaving group L ⁇ is halogen e.g. chloro group and the reaction may be carried out in an inert organic solvent such as tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.
  • an inert organic solvent such as tetrahydrofuran or dichloromethane
  • a base such as triethylamine or pyridine.
  • Carboxylic acid groups can be protected as esters.
  • Aldehyde or ketone groups can be protected as acetals, ketals, thioacetals or thioketals. Deprotection is achieved using standard conditions. The involvement of serotonin receptors in a number of pharmacological effects has been reviewed by R. A. Glennon in "Serotonin Receptors: Clinical Implications", Neuroscience and Behavioural Reviews, 1990, J_4, 35 and by L.O.Wilkinson and C.T. Dourish in "Serotonin Receptor Subtypes : Basic and Clinical Aspects" S. Peroutka Ed., John Wiley and Sons, New York, 1991 ⁇ .147.
  • Serotonin (5-hydroxytryptamine; 5-HT) receptors have been implicated in a number of pharmacological effects including mood disorders including depression, seasonal affective disorder and dysthymia, anxiety disorders, including generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder; memory disorders, including dementia, amnesic disorders and age-associated memory impairment; disorders of eating behaviours, including anorexia nervosa and bulimia nervosa, sleep disorders (including disturbances of Circadian rhythm), motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders.
  • mood disorders including depression, seasonal affective disorder and dysthymia
  • anxiety disorders including generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder
  • memory disorders including dementia, amnesic disorders and
  • Serotonin receptor ligands have been shown to be of use in the treatment of emesis and nausea and may also be of use in endocrine disorders such as hyperlactinaemia, vasospasm (particularly in the cerebral vasculature), cerebellar ataxia and hypertension, as well as disorders of the gastrointestinal tract where changes in motility and secretion are involved. They may also be of use in the treatment of sexual dysfunction and hypothermia.
  • WO 95/31988 refers to the use of a 5-HT ⁇ rj receptor antagonist in conjunction with a 5-HT ⁇ A receptor antagonist to treat CNS (central nervous system), endocrine and GI (gastrointestinal) disorders;
  • K. Rasmussen Annual Reports in Medicinal Chemistry, (1995) 30, 1) describes the utility of 5-HTj A receptor agonists and partial agonists in the treatment of various CNS disorders;
  • P. Trouillas Progress in Brain Research, CI. de Zeeuw, P. Stara and J. Voogd, Eds. 1997, 144, 589) and G. Maura (J. Neurochemistry, 1996, 66, 202) propose that administration of agonist ligands selective for the 5-HT ⁇ A receptor or for both 5-HTi A and 5-HT ID receptors should provide effective treatment for human cerebellar ataxias.
  • the present invention also provides a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of the aforementioned disorders.
  • the invention provides a method of treating the aforementioned disorders which comprises administering an effective amount to a patient in need of such treatment of a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • the invention provides a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in the treatment or prophylaxis of depression.
  • the affinities of the compounds of this invention for the 5-HT ⁇ A, 5-HTI g and 5-HTiD receptors can be determined by the following radioligand binding assay.
  • HEK 293 cells expressing 5-HTJA. receptors (4 x lO ⁇ /ml) are homogenised in Tris buffer and stored in lml aliquots.
  • CHO cells expressing 5-HTIJJ receptors (4 x 10? cells/ml) are homogenised in Tris buffer and stored in 1.5 ml aliquots.
  • CHO cells expressing 5-HTID receptors (0.563 x 10 ⁇ /ml) are homogenised in Tris buffer and stored in 1 ml aliquots.
  • the intrinsic activity of the compounds of this invention can be determined according to the following procedure.
  • HEK-293 cell membranes stably expressing human 5-HT 1 A receptors and CHO cell membranes stably expressing human 5-HT ⁇ g receptors are homogenised in HEPES/EDTA buffer and stored in lml aliquots, and [35s]GTP ⁇ S binding studies are carried out essentially as described by Lazareno et al, (Life Sci., 1993, 52, 449) with some minor modifications.
  • Membranes from 10 ⁇ cells are pre-incubated at 30°C for 30 min in 20 mM HEPES buffer (pH 7.4) in the presence of MgCl 2 (3 mM), NaCl (100 mM), GDP (10 ⁇ M) and ascorbate (0.2 mM), with or without compounds.
  • the reaction is started by the addition of 10 ⁇ l of [35s]GTP ⁇ S (100 pM, assay concentration) followed by a further 30 minutes incubation at 30°C.
  • Non-specific binding was determined using non- radiolabelled GTP ⁇ S (20 ⁇ M) added prior to the membranes.
  • the reaction is terminated by rapid filtration through Whatman GF/B grade filters followed by 5 x 1 ml washes with ice cold HEPES (20 mM) /MgCl 2 (3 mM) buffer. Radioactivity is measured using liquid scintillation spectrometry. This procedure is hereafter referred to as the [35s]GTP ⁇ S functional assay.
  • the compounds of formula (I) show high affinity for the 5-HT ⁇ A, 5-HTi g and 5-HT ⁇ ) receptors.
  • the preferred compounds of this invention will display 5-HTJA, 5-HTH3 and 5-HTjr) antagonist activity in vivo and that such compounds will have a rapid onset of action.
  • a rapid onset of action is particularly advantageous for antidepressant compounds: by 'rapid onset of action' we mean that a therapeutic response is seen within 7 days from first administration of the compound, as opposed to a period of about 21 days or more which is typical of SSRI's, tricyclic antidepressants and buspirone.
  • the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, a selective serotonin reuptake inhibitor (SSRI) antidepressant.
  • SSRI selective serotonin reuptake inhibitor
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
  • Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.
  • fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.
  • the 1,2-dimethoxyethane was removed in vacuo and the residue diluted with 2M NaOH solution and washed with EtOAc.
  • the aqueous phase was acidified to pHl with cone. HCl and washed with EtOAc, then adjusted to pH5 with K 2 CO3 and extracted with DCM (3x).
  • the DCM extracts were combined, dried (Na SO4) and concentrated in vacuo, giving the title compound as a white solid (1.38 g, 70%).
  • the title compound was prepared from 4-bromo-2,5-dimethylpyridine and 5-carboxynaphth-
  • Ethyl 5-bromoacetyl-l-naphthoate (D30, 3.50 g, 10.9 mmole) was dissolved in DCM (40 ml) and cooled in an ice bath to ⁇ 5°C. This solution was treated with tetrabutylammonium iodide (0.20 g, 0.54 mmole) and a solution of sodium azide (1.06 g, 16.3 mmole) in water (8 ml) and stirred vigorously for 3 h, while warming to room temperature. Water (30 ml) was added and the organic phase separated, dried (Na SO4) an£ I concentrated carefully in vacuo to approx. 20 ml volume.
  • Ethyl 5-aminoacetyl-l-naphthoate hydrochloride (D31, 2.26 g, 7.70 mmole) was suspended with stirring in DCM (60 ml) and treated with triethylamine (1.2 ml, 8.50 mmole) and acetic anhydride (0.86 g, 8.5 mmole). After 18 h, the mixture was concentrated to dryness in vacuo and the residue partitioned between EtOAc and 10% aqueous Na 2 CO3 solution. The organic phase was separated, dried (Na 2 SO4), concentrated to dryness in vacuo and purified by silica gel chromatography, eluting with EtOAc, to afford the title compound as a white solid (1.73 g, 60%).
  • Ethyl 5-acetamidoacetyl-l-naphthoate (D33, 1.71 g, 5.72 mmole) was covered with polyphosphoric acid ( ⁇ 48 g) and the resulting viscous mixture was heated with stirring, under argon. On reaching 140°C, the mixture was partially cooled and poured into a beaker of crushed ice ( ⁇ 50 ml) with stirring. Water (50 ml) was added and the solution extracted with EtOAc.
  • the title compound was prepared from (S)-(-)-2,3-dihydro-8-(octahydropyrrolo[l,2- ⁇ ]pyrazin-2-yl)pyrrolo[2,3-g]quinoline (D10, 100 mg, 0.34 mmole) and 5-(2,6- dimethylpyridin-4-yl)naphthoyl chloride (D14, 150 mg, 0.51 mmole) using a similar procedure to Example 2, as a cream coloured solid (31 mg, 16%).
  • the title compound was prepared from (S)-(-)-2,3-dihydro-8-(octahydropyrrolo[l,2- fl]pyrazin-2-yl)pyrrolo[2,3-g-]quinoline (D10, 85 ⁇ mole), and 2,3-dichlorobenzoic acid (255 ⁇ mole) using a similar procedure to Example 4, as a yellow glass (51%).
  • the title compound was prepared from (S)-(-)-2,3-dihydro-8-(octahydropyrrolo[l,2- ⁇ ]pyrazin-2-yl)pyrrolo[2,3-g]quinoline (D10, 85 ⁇ mole) and 4-(5-methyloxazol-2-yl)-l- naphthoic acid (D21, 255 ⁇ mole) using a similar procedure to Example 4, as a brown glass (47%).
  • the title compound was prepared from (S)-(-)-2,3-dihydro-8-(octahydropyrrolo[l,2- ⁇ ]pyrazin-2-yl)pyrrolo[2,3-g]quinoline (D10, 85 ⁇ mole), and 5-(5-methylpyridin-2-yl)-l- naphthoic acid (D16, 255 ⁇ mole) using a similar procedure to Example 4.
  • the compound was further purified using reverse phase HPLC and isolated as the trifluoroacetate salt, as a pale brown glass (20%).
  • the title compound was prepared from (S)-(-)-2,3-dihydro-8-(octahydropyrrolo[l,2- ⁇ ]pyrazin-2-yl)pyrrolo[2,3-g]quinoline (D10, 85 ⁇ mole), and 5-(6-methylpyridin-2-yl)-l- naphthoic acid (D17, 255 ⁇ mole) using a similar procedure to Example 4, as a yellow glass (46%).
  • the title compound was prepared from (S)-(-)-2,3-dihydro-8-(octahydropyrrolo[l,2- ⁇ ]pyrazin-2-yl)pyrrolo[2,3- ]quinoline (D10, 85 ⁇ mole), and 5-(3-methylpyridin-2-yl)-l- naphthoic acid (D23, 255 ⁇ mole) using a similar procedure to Example 4, as a pale yellow glass (64%).
  • the title compound was prepared from (S)-(-)-2,3-dihydro-8-(octahydropyrrolo[l,2- ⁇ ]pyrazin-2-yl)pyrrolo[2,3- ]quinoline (D10, 85 ⁇ mole), and 5-(2-methyloxazol-5-yl)-l- naphthoic acid (D34, 255 ⁇ mole) using a similar procedure to Example 4, as a yellow glass (36%).
  • the title compound was prepared from (S)-(-)-2,3-dihydro-8-(octahydropyrrolo[l,2- ⁇ ]pyrazin-2-yl)pyrrolo[2,3-g]quinoline (D10, 85 ⁇ mole), and 5-(3-methylisoxazol-5-yl)-l- naphthoic acid (D36, 255 ⁇ mole) using a similar procedure to Example 4, as a yellow glass (26%).
  • the title compound was prepared from (S)-(-)-2,3-dihydro-8-(octahydropyrrolo[l,2- ⁇ ]pyrazin-2-yl)pyrrolo[2,3-g]quinoline (D10, 170 ⁇ mole), and 2-(4-chlorophenyl)-3- trifluoromethylpyrazole-4-carboxylic acid (250 ⁇ mole) using a similar procedure to Example 4, as a yellow glass (52%).
  • the title compound was prepared from (S)-(-)-2,3-dihydro-8-(octahydropyrrolo[l,2- ⁇ ]pyrazin-2-yl)pyrrolo[2,3-g-]quinoline (D10, 170 ⁇ mole), and 5-(2-methyl-5- trifluoromethylpyrazol-3-yl)-thiophen-2-carboxylic acid (250 ⁇ mole) using a similar procedure to Example 4, as a yellow glass (80%).
  • Examples E25 - E72 were prepared in parallel using a similar procedure to that described for Example 4.
  • the title compound was prepared from (S)-(-)-2,3-dihydro-8-(octahydropyrrolo[l,2- ⁇ ]pyrazin-2-yl)pyrrolo[2,3-g]quinoline (DIO, 85 ⁇ mole), and 5-(5-methyloxazol-2- yl)naphth-l-ylacetic acid (D27, 255 ⁇ mole) using a similar procedure to Example 4, as a pale brown glass (70%).
  • Examples E75 - E80 were prepared in parallel using a similar procedure to that as described for Example E74.
  • the affinities of the compound of this invention was determined using the radiolabelled binding assay as described above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention concerne des dérivés quinoliniques pharmacologiquement actifs, des procédés permettant leur élaboration, des compositions les contenant et leur utilisation pour le traitement de troubles du système nerveux central.
EP99964526A 1998-12-17 1999-12-03 Composes Withdrawn EP1140946A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9827882 1998-12-17
GBGB9827882.3A GB9827882D0 (en) 1998-12-17 1998-12-17 Novel compounds
PCT/EP1999/009564 WO2000035919A2 (fr) 1998-12-17 1999-12-03 Composes

Publications (1)

Publication Number Publication Date
EP1140946A2 true EP1140946A2 (fr) 2001-10-10

Family

ID=10844468

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99964526A Withdrawn EP1140946A2 (fr) 1998-12-17 1999-12-03 Composes

Country Status (17)

Country Link
EP (1) EP1140946A2 (fr)
JP (1) JP2002532501A (fr)
KR (1) KR20010108028A (fr)
CN (1) CN1335850A (fr)
AU (1) AU3036000A (fr)
BR (1) BR9916307A (fr)
CA (1) CA2355234A1 (fr)
CO (1) CO5150146A1 (fr)
CZ (1) CZ20012151A3 (fr)
GB (1) GB9827882D0 (fr)
HK (1) HK1041480A1 (fr)
HU (1) HUP0104662A2 (fr)
IL (1) IL143782A0 (fr)
NO (1) NO20013003L (fr)
PL (1) PL353156A1 (fr)
TR (1) TR200101764T2 (fr)
WO (1) WO2000035919A2 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9926303D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
PT1397130E (pt) 2001-06-20 2007-11-13 Wyeth Corp Derivados ácidos de indole substituído como inibidores de inibidor 1 do activador de plasminogénio (pai-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
EP1844771A3 (fr) * 2001-06-20 2007-11-07 Wyeth Dérives d'acide indole substitue utilises en tant qu'inhibiteurs de l'inhibiteur-1 (PAI-1) de l'activateur plasminogene
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
DK1569900T3 (da) 2002-12-10 2006-10-23 Wyeth Corp Substituerede 3-carbonyl-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DE60327550D1 (de) 2002-12-10 2009-06-18 Wyeth Corp Substituierte indoloxoacetylaminoessigsäurederivate als inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
AU2003296324A1 (en) 2002-12-10 2004-06-30 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
KR100807920B1 (ko) 2003-12-23 2008-02-27 화이자 인코포레이티드 신규한 퀴놀린 유도체
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US8815271B2 (en) 2010-11-03 2014-08-26 Dow Agrosciences, Llc. Pesticidal compositions and processes related thereto
MX355431B (es) 2011-10-26 2018-04-18 Dow Agrosciences Llc Composiciones plaguicidas y procesos relacionados con dichas composiciones.
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
CN105732580B (zh) 2012-04-27 2018-12-07 陶氏益农公司 杀虫组合物和与其相关的方法
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
CA2925914A1 (fr) 2013-10-17 2015-04-23 Dow Agrosciences Llc Procedes de preparation de composes pesticides
BR112016008070B8 (pt) 2013-10-17 2022-08-23 Dow Agrosciences Llc Compostos pesticidas, e seus processos de preparação
CN105636443A (zh) 2013-10-17 2016-06-01 美国陶氏益农公司 制备杀虫化合物的方法
JP2016539092A (ja) 2013-10-17 2016-12-15 ダウ アグロサイエンシィズ エルエルシー 有害生物防除性化合物の製造方法
WO2015058021A1 (fr) 2013-10-17 2015-04-23 Dow Agrosciences Llc Procédés de préparation de de composés pesticides
WO2015058026A1 (fr) 2013-10-17 2015-04-23 Dow Agrosciences Llc Procédés de préparation de composés pesticides
CA2925952A1 (fr) 2013-10-17 2015-04-23 Dow Agrosciences Llc Procedes de preparation de composes pesticides
RU2016119566A (ru) 2013-10-22 2017-11-28 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Синергетические пестицидные композиции и относящиеся к ним способы
WO2015061140A1 (fr) 2013-10-22 2015-04-30 Dow Agrosciences Llc Compositions pesticides synergiques et méthodes associées
AU2014340422B2 (en) 2013-10-22 2017-06-29 Corteva Agriscience Llc Pesticidal compositions and related methods
CN105848480A (zh) 2013-10-22 2016-08-10 美国陶氏益农公司 协同杀虫组合物和相关方法
JP2016538266A (ja) 2013-10-22 2016-12-08 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
JP2016535026A (ja) 2013-10-22 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
EP3060054A4 (fr) 2013-10-22 2017-04-05 Dow AgroSciences LLC Compositions pesticides synergiques et procédés associés
CA2926647A1 (fr) 2013-10-22 2015-04-30 Dow Agrosciences Llc Compositions pesticides et procedes associes
NZ719952A (en) 2013-10-22 2017-05-26 Dow Agrosciences Llc Pesticidal compositions and related methods
KR20160074637A (ko) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 살충 조성물 및 관련 방법
RU2016119531A (ru) 2013-10-22 2017-11-28 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Синергические пестицидные композиции и связанные с ними способы
US9788545B2 (en) 2013-10-22 2017-10-17 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
TW201517797A (zh) 2013-10-22 2015-05-16 Dow Agrosciences Llc 協同性殺蟲組成物及相關方法（十一）
WO2015061151A1 (fr) 2013-10-22 2015-04-30 Dow Agrosciences Llc Compositions pesticides et procédés associés
RU2016119560A (ru) 2013-10-22 2017-11-28 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Синергетические пестицидные композиции и относящиеся к ним способы
KR20160074640A (ko) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 살충 조성물 및 관련 방법
CA2927198A1 (fr) 2013-10-22 2015-04-30 Dow Agrosciences Llc Compositions pesticides synergiques et procedes associes
US9249122B1 (en) 2014-07-31 2016-02-02 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
KR20170038785A (ko) 2014-07-31 2017-04-07 다우 아그로사이언시즈 엘엘씨 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
JP2017523168A (ja) 2014-07-31 2017-08-17 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの製造方法
JP2017525703A (ja) 2014-08-19 2017-09-07 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの調製方法
BR112017004613A2 (pt) 2014-09-12 2017-12-05 Dow Agrosciences Llc processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina
CN110325036B (zh) 2016-12-29 2021-10-26 美国陶氏益农公司 用于制备杀虫化合物的方法
JP2020503336A (ja) 2016-12-29 2020-01-30 ダウ アグロサイエンシィズ エルエルシー 殺有害生物化合物の調製方法
CN108570450A (zh) * 2017-03-11 2018-09-25 华中科技大学鄂州工业技术研究院 一种细胞模型及其构建和筛选五羟色胺受体靶点活性物质之应用
CN106883192B (zh) * 2017-03-30 2019-05-14 苏州汉德创宏生化科技有限公司 含氮类杂环抗肿瘤药物活性物恶唑基修饰的苯甲酸类化合物的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0716656A1 (fr) * 1993-09-03 1996-06-19 Smithkline Beecham Plc Derives d'amide en tant qu'antagonistes du recepteur de 5ht1d
CN1260781A (zh) * 1997-04-18 2000-07-19 史密丝克莱恩比彻姆有限公司 具有综合的5ht1a、5ht1b和5ht1d受体拮抗剂活性的吲哚衍生物
WO1998047868A1 (fr) * 1997-04-18 1998-10-29 Smithkline Beecham Plc Derives d'uree contenant un heterocycle utilises comme antagonistes des recepteurs 5ht1a, 5ht1b et 5ht¿1d?
EP1047691A1 (fr) * 1997-12-12 2000-11-02 Smithkline Beecham Plc Derives de quinoleinepiperazine et de quinoleinepiperidine, leur preparation et leur utilisation en tant qu'antagonistes combines des recepteurs 5-ht1a, 5-ht1b et 5-ht1d

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0035919A2 *

Also Published As

Publication number Publication date
KR20010108028A (ko) 2001-12-07
NO20013003D0 (no) 2001-06-15
TR200101764T2 (tr) 2001-10-22
CN1335850A (zh) 2002-02-13
CZ20012151A3 (cs) 2001-12-12
CA2355234A1 (fr) 2000-06-22
HUP0104662A2 (hu) 2002-04-29
CO5150146A1 (es) 2002-04-29
PL353156A1 (en) 2003-10-20
WO2000035919A3 (fr) 2000-10-26
NO20013003L (no) 2001-07-25
GB9827882D0 (en) 1999-02-10
WO2000035919A2 (fr) 2000-06-22
AU3036000A (en) 2000-07-03
IL143782A0 (en) 2002-04-21
BR9916307A (pt) 2002-01-15
HK1041480A1 (zh) 2002-07-12
JP2002532501A (ja) 2002-10-02

Similar Documents

Publication Publication Date Title
EP1140946A2 (fr) Composes
EP1551835B1 (fr) Derives de 1,4-diazabicycloalkane, preparation et utilisation
US5589476A (en) Imidazol-4-ylpiperidine derivatives, their preparation and their application in therapeutics
EP1301514B1 (fr) Diazabicycloalkanes aryle et heteroaryle, elaboration et utilisation
EP2172469A1 (fr) Dérivés aryle diazabicycliques comme modulateurs des récepteurs cholinergiques
CN101115751A (zh) 三环δ-阿片样物质调节剂
EP1866314A1 (fr) Derives aryle diazabicycliques et utilisation medicale
JP2007520527A (ja) ニコチン性アセチルコリン受容体リガンドとしてのジアザ２環式アリール誘導体
US7271162B2 (en) Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
KR20080079250A (ko) 신규한 디아자바이사이클릭 아릴 유도체 및 이의 의학적용도
EP1599476B1 (fr) Derives aryle diazabicycliques
EP1003738B1 (fr) Composes bicycliques servant de ligands pour les recepteurs 5-ht1
EP1228043B1 (fr) Derives d'isoquinoline et de quinazoline dotes d'une activite combinee de recepteur 5ht1a, 5ht1b et 5ht1d
EP0320136A2 (fr) Composés d'imidazoquinoxaline, leur préparation et utilisation
KR20010053136A (ko) 치환된 트리아졸로-피리다진 유도체 및 이로부터 제조된약제학적 조성물
CN101119992A (zh) 三环δ阿片样物质调节剂
JP2002501069A (ja) Ｇａｂａ受容体のためのリガンドとしてのトリアゾロ−ピリダジン誘導体
CA2588961A1 (fr) Nouveaux derives aryliques diazabicycliques utilises en tant que ligands cholinergiques
WO2000006575A2 (fr) Nouveaux composes
JP2000503997A (ja) 縮合した２，３―ベンゾジアゼピン誘導体及びａｍｐａ―レセプター抑制剤としての使用
JPH09512025A (ja) ５ｈｔ▲下２ｃ▼および５ｈｔ▲下２ｂ▼アンタゴニストとしての三環式誘導体
EP1233965A1 (fr) Derives d'isoquinoline et de quinazoline destines au traitement des troubles du snc
RU2345995C2 (ru) Соль метансульфоновой кислоты пиразолпиримидинового соединения, его кристалл и способ его получения
MXPA01006243A (en) Compounds
WO1999029666A1 (fr) Derives d'arylpiperazine et d'arylpiperidine, leur mise au point et leur utilisation en tant qu'antagonistes des recepteurs de 5-ht1a, 5-ht1b et 5-ht1d combines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010709

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI PAYMENT 20010709

17Q First examination report despatched

Effective date: 20011105

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020516

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1041480

Country of ref document: HK